Skip to main content

What Do Sanofi And Dexcom See In DarioHealth That The Market Is Missing?

--News Direct--

  1. Dexcom and Dario think alike when it comes to the elements of an effective solution: user engagement, health outcomes, and return on investment.

  2. Diabetics are likely to have more than one chronic condition, Dario’s engaging and highly rated multi-chronic condition platform leads to better clinical outcomes and delivers a measurable ROI.

  3. Dario’s platform leapfrogs Dexcom’s mission (slide 24) “Where the company is going: Type 2 Non-Insulin, Pre-Diabetes, Patient Monitoring, and Health & Wellness”.

  4. The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions.

  5. Market overlooking global industry leaders: Sanofi, Aetna, and now Dexcom validating DarioHealth’s revolutionization in healthcare management of people with single or multi-chronic conditions through a user-centric platform.

DarioHealth is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Dario’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers.

Dario’s user-centric platform offers people continuous and customized care for health, disrupting the traditional, doctor centric, episodic approach to healthcare. Dario’s platform empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and improved health outcomes which result in a measurable ROI to payors.

Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support.

The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions. On March 1, 2022, Dario entered a multi-year $30 million-dollar strategic agreement with Sanofi U.S.(EURONEXT: SAN and NASDAQ: SNY) designed to accelerate commercial adoption and drive the expansion of digital health solutions on the Dario platform. Sanofi selected Dario to leverage its broad suite of digital therapeutics and its ability to engage patients for favorable clinical and financial outcomes, as the solution of choice for its U.S. commercial clients.

Strategic partnerships with Sanofi, Virgin Pulse, Solera and Alliant give Dario access to more than 10,000 employers and more than 50 health plans as potential clients for the platform.

Dario’s preliminary results demonstrate successful B2C to B2B transformation.

Total revenue for the year is expected to be $27.5 million compared to $20.5 million in 2021. Higher revenues on lower spend demonstrates that the strategy of moving from B2C to B2B sales channels has resulted in an overall significant improvement in the financial profile of the Company. The Company reduced its operating loss by more than 30% compared to the third quarter ended September 30, 2022, and by more than 50% compared to the fourth quarter of 2021. DarioHealth had $49.3 million of cash and cash equivalents at the end of 2022.

Dexcom’s global leadership position in CGM delivers solid results

On February 9th, 2023, Dexcom Reported 2022 Financial Results. Full year revenue grew 19% to $2.91 billion. GAAP operating income totaled $391.2 million or 13.4% of revenue. Dexcom delivered record new customer starts, drove multiple new product launches, and significantly expanded access to Dexcom CGM around the world. As of December 31, 2022, Dexcom held $2.46 billion in cash or equivalents.

Sanofi delivers strong sales performance and double digit EPS growth

On February 3rd, 2023, Sanofi (EURONEXT: SAN and NASDAQ: SNY) reported full year 2022 results highlighting 7% sales growth to 43 Billion Euro and 17% EPS growth. Free cash flow from operations totaled 8.5 Billion Euro. Sanofi is an innovative global healthcare company chasing miracles of science to improve people’s lives. The Company provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, sustainably and socially responsible.

RCA Financial Partners Inc. ("RCA Partners" or "we" is a consulting and advisory firm to small public and pre-IPO data resource innovators at the critical inflection point where proven technology requires prudent financing for success. We help our clients connect with well informed investors. To learn more about RCA Financial Partners and its data resource innovators, visit

Disclaimers: This article contains sponsored content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. RazorPitch authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. RazorPitch has not been compensated to produce and syndicate this content. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website.

This summary report was prepared by RCA Financial Partners and distributed by RazorPitch. RCA Financial Partners is not a securities broker-dealer, an investment adviser, or a bank, and, accordingly, this report is not subject to FINRA or SEC rules regarding broker-dealer securities research, nor to the regulations to which investment advisers or banks are subject, including regulations regarding independence of written communications. RCA has been retained and compensated by the subject company of this report. This report does not constitute, and should not be construed as an independent analysis of the subject company, or as an offer to buy or sell, or a solicitation of an offer to buy or sell any security. This report is published without regard to the specific needs of any person, and it does not take into account the particular financial situation or needs of any individual. Readers should seek professional financial advice, including tax advice, before taking any investment decision. This report is based on information that we believe to be reliable, but RCA Financial Partners does not make any express or implied representation or warranty as to the completeness, reliability, or accuracy of information contained in this report, or of information used to create this report.

Further important disclosures and disclaimers are available at:

Contact Details

Mark McKelvie

+1 585-301-7700

Company Website

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.